MedTrace Logo

A Study of ZW251 in Participants With Advanced Solid Tumors

NCT07164313 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-05-07

No results posted yet for this study

Summary

The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma (HCC), squamous cell non-small cell lung cancer (NSCLC), or germ cell tumors (GCT).

Conditions

Interventions

DRUG

ZW251

Administered intravenously

Sponsors & Collaborators

  • Zymeworks BC Inc.

    lead INDUSTRY

Principal Investigators

  • Maggie Weinstein, MD, PhD, MPH · Zymeworks BC Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-21
Primary Completion
2027-09-30
Completion
2028-05-31
FDA Drug
Yes

Countries

  • United States
  • Ireland
  • Japan
  • Portugal
  • Spain
  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07164313 on ClinicalTrials.gov